Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.

Also called NCT02252965

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 532 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02252965
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02252965. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2017-01-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
Acronym
CONSENT
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Metformin IR
Intervention (Drug)
Metformin XR
Lead sponsor
Merck KGaA, Darmstadt, Germany (class: industry)

Record details

Record id
cardio:ct-nct02252965
Content hash
bd55ec67d179e9319e70e67a2da8e06ef11e788b8da6b67815b5344010390ae1